Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)
:SUNPHARMA
Want to see IN:SUNPHARMA full AI Analyst Report?
Top Page
Sun Pharmaceutical Industries Limited
(SUNPHARMA)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹1,916.00
▲(10.74% Upside)
Action:ReiteratedDate:04/28/26
Score is driven primarily by strong financial performance (profitability expansion, low leverage, and robust cash generation). This is tempered by mixed technical momentum (negative MACD) and a relatively high P/E with only a modest dividend yield.
Positive Factors
Strong cash generation
Sun Pharma's operating cash flow exceeds reported net income and free cash flow grew 20.2% year-over-year. This durable cash conversion capacity supports sustained funding for R&D, capex, dividends or M&A without relying on external financing, improving long-term financial flexibility.
Negative Factors
Exposure to generics pricing pressure
Significant exposure to commoditized generics, especially in the U.S., subjects core revenue to structural price erosion and customer consolidation. Over months to years, persistent pricing competition can compress margins and force continual new launches to sustain growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Sun Pharma's operating cash flow exceeds reported net income and free cash flow grew 20.2% year-over-year. This durable cash conversion capacity supports sustained funding for R&D, capex, dividends or M&A without relying on external financing, improving long-term financial flexibility.
Read all positive factors
Sun Pharmaceutical Industries Limited (SUNPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.89T
Dividend Yield0.91%
Average Volume (3M)102.58K
Price to Earnings (P/E)30.6
Beta (1Y)0.55
Revenue Growth10.09%
EPS Growth-4.53%
CountryIN
Employees43,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)14.70
Shares Outstanding2,399,278,300
10 Day Avg. Volume56,056
30 Day Avg. Volume102,581
Financial Highlights & Ratios
PEG Ratio2.61
Price to Book (P/B)5.64
Price to Sales (P/S)7.74
P/FCF Ratio34.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,916.33Price Target Upside10.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)56.18
Revenue Forecast (FY)₹646.96B
Sun Pharmaceutical Industries Limited Business Overview & Revenue Model
Company Description
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulation...
How the Company Makes Money
Sun Pharma primarily makes money by selling pharmaceutical products (finished dosage formulations) and, to a lesser extent, APIs to customers in India and international markets. Its core revenue stream is the commercialization of prescription medi...
Sun Pharmaceutical Industries Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 549.64B | 525.78B | 484.97B | 438.86B | 386.54B | 334.98B |
| Gross Profit | 359.81B | 410.20B | 370.55B | 325.67B | 277.78B | 242.80B |
| EBITDA | 165.42B | 149.68B | 128.76B | 116.51B | 101.54B | 83.45B |
| Net Income | 104.50B | 109.29B | 95.76B | 84.74B | 32.73B | 29.04B |
Balance Sheet | ||||||
| Total Assets | 1.04T | 921.01B | 854.63B | 807.44B | 698.00B | 676.67B |
| Cash, Cash Equivalents and Short-Term Investments | 278.80B | 249.88B | 190.90B | 159.07B | 126.55B | 95.63B |
| Total Debt | 52.15B | 23.62B | 32.74B | 68.90B | 12.90B | 38.69B |
| Total Liabilities | 255.80B | 196.15B | 183.57B | 214.28B | 187.34B | 181.87B |
| Stockholders Equity | 778.20B | 722.18B | 636.67B | 559.95B | 480.11B | 464.63B |
Cash Flow | ||||||
| Free Cash Flow | 23.93B | 119.44B | 99.33B | 28.74B | 74.89B | 50.00B |
| Operating Cash Flow | 47.81B | 140.72B | 121.35B | 49.59B | 89.85B | 61.70B |
| Investing Cash Flow | -66.91B | -53.06B | -6.90B | -79.44B | -57.25B | 5.36B |
| Financing Cash Flow | 11.01B | -79.06B | -67.10B | 23.76B | -51.93B | -59.80B |
Sun Pharmaceutical Industries Limited Technical Analysis
Negative
1730.15
Price Trends
1735.86
Negative
1732.20
Negative
1689.28
Negative
Market Momentum
-20.82
Positive
40.58
Neutral
43.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUNPHARMA, the sentiment is Negative. The current price of 1730.15 is above the 20-day moving average (MA) of 1729.58, below the 50-day MA of 1735.86, and above the 200-day MA of 1689.28, indicating a bearish trend. The MACD of -20.82 indicates Positive momentum. The RSI at 40.58 is Neutral, neither overbought nor oversold. The STOCH value of 43.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUNPHARMA.
Sun Pharmaceutical Industries Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹1.69T | 72.71 | ― | 0.46% | 13.62% | 19.93% | |
72 Outperform | ₹1.10T | 21.88 | ― | 0.63% | 11.01% | 5.28% | |
72 Outperform | ₹1.05T | 20.49 | ― | 0.57% | 18.86% | 61.69% | |
71 Outperform | ₹3.89T | 30.62 | ― | 0.91% | 10.09% | -4.53% | |
68 Neutral | ₹1.05T | 45.14 | ― | 0.87% | 5.08% | -8.91% | |
66 Neutral | ₹1.39T | 51.30 | ― | 0.84% | 12.74% | 22.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,747.70
-39.57
-2.21%
IN:CIPLA
Cipla Ltd
1,308.05
-216.65
-14.21%
IN:DIVISLAB
Divi's Laboratories Limited
6,433.90
349.70
5.75%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,354.75
185.91
15.91%
IN:LUPIN
Lupin Limited
2,302.10
247.47
12.04%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,183.20
890.27
27.04%
Sun Pharmaceutical Industries Limited Corporate Events
Sun Pharma to Buy Organon in US$ 11.75 Billion All‑Cash Deal
Apr 27, 2026
Sun Pharmaceutical Industries has signed a definitive agreement to acquire U.S.‑listed Organon Co. in an all‑cash transaction valuing Organon at an enterprise value of US$ 11.75 billion, with shareholders receiving US$ 14.00 per share...
Sun Pharma to Host Investor Call on Organon Acquisition
Apr 27, 2026
Sun Pharmaceutical Industries has scheduled an investor call on April 27, 2026, at 8:00 a.m. IST to discuss its planned acquisition of Organon Co., signaling a potentially significant expansion of its portfolio and global footprint. Senior manage...
Sun Pharma Shares Investor Presentation on Global Transformation Strategy
Apr 27, 2026
Sun Pharmaceutical Industries Limited has notified the stock exchanges that it has prepared and shared an investor presentation, in line with Indian listing regulations. The presentation, titled around accelerating Sun Pharma’s transformatio...
Sun Pharma Shareholders Clear Postal Ballot Resolutions, Renew Independent Director
Apr 17, 2026
Sun Pharmaceutical Industries Limited has concluded a postal ballot process initiated in March 2026, with shareholders approving all resolutions proposed by the board. The approvals reflect continued shareholder support for the company’s gov...
Sun Pharma Publishes Postal Ballot and E-Voting Notices for Shareholders
Apr 8, 2026
Sun Pharmaceutical Industries Limited has notified the stock exchanges that it has published newspaper advertisements in all editions of the Financial Express in English and the Ahmedabad edition in Gujarati. These advertisements provide informati...
Sun Pharma, Philogen Advance Nidlegy After Mixed Fibromun Trial Results
Mar 27, 2026
Sun Pharmaceutical Industries, in collaboration with partner Philogen, reported mixed clinical outcomes for its oncology candidate Fibromun, with Phase II trials in last-line soft tissue sarcoma and second-line glioblastoma failing to meet primary...
Sun Pharma Publishes Q3 FY26 Unaudited Results Notice in Newspapers
Feb 1, 2026
Sun Pharmaceutical Industries Limited has notified the stock exchanges that it has published newspaper advertisements in the Financial Express (all editions) and the Vadodara edition of Loksatta Jansatta, providing information on its unaudited fin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.